Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.

PloS one - 1 Jan 2017

Rojas Sánchez Patricia, Prieto Luis, Jiménez De Ory Santiago, Fernández Cooke Elisa, Navarro Maria Luisa, Ramos José Tomas, Holguín África

Abstract excerpt

BACKGROUND: The most-used protease-inhibitor in children is Lopinavir-ritonavir (LPV/r), which provides durable suppression of viral load and increases CD4+T-counts. This study describes the virological outcome of the HIV-1-infected paediatric population exposed to LPV/r during 15 years in Spain. METHODOLOGY: Patients from the Madrid Cohort of HIV-1-infected-children and adolescents exposed to LPV/r as different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-CD8 Ratio
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to HIV Protease Inhibitors

Share to Host-Pathogen Interactions

Share to Lopinavir

Share to Ritonavir

Share to Viremia

Source

Open in PubMed Open full text

Identifiers

PMID: 28350802
DOI: 10.1371/journal.pone.0173168
PMCID: PMC5369685

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.PMID 28350802Read ↗

Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis.Semantic proximity Read ↗

Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.Semantic proximity Read ↗

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.Semantic proximity Read ↗

Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006-17): impact on susceptibility to first-line strategies.Semantic proximity Read ↗

High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain.Semantic proximity Read ↗

Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio de Janeiro, Brazil.Semantic proximity Read ↗

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.Semantic proximity Read ↗

Transmitted Drug Resistance and HIV Diversity Among Adolescents Newly Diagnosed With HIV in Spain.Semantic proximity Read ↗

HIV-1 Diversity and Drug Resistance in Treatment-Naïve Children and Adolescents from Rio de Janeiro, Brazil.Semantic proximity Read ↗

Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade.Semantic proximity Read ↗

Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Semantic proximity Read ↗

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.